Biotheranostics Competitors and Similar CompaniesClear all

Biotheranostics's competitors and similar companies include Personalis, Exact Sciences, Genoptix and Biocept.

	Biotheranostics Biotheranostics is a molecular diagnostics company that develops and provides diagnostic, prognostic, and predictive tests that helps physicians in the treatment of cancer patients.	Personalis Personalis is a biotechnology company that specializes in cancer genomics.	Exact Sciences Exact Sciences is a company that provides cancer screening and diagnostic test products.	Genoptix Genoptix is a company operating as a specialty oncology laboratory.	Biocept Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer.
Founding Date	Founding Date 2008	Founding Date 2011	Founding Date 1995	Founding Date 1999	Founding Date 1993
Type	Type Private	Type Public	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech medical diagnostics oncology	Tags Technology biotech genetics platform	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics oncology	Tags Healthcare biotech medical diagnostics oncology
Locations	Locations San Diego, US HQ	Locations Fremont, US HQ West Wickham, GB	Locations Madison, US HQ Paris, FR Cologne, DE Milan, IT Tokyo, JP Baar, CH London, GB see more	Locations Carlsbad, US HQ	Locations San Diego, US HQ
Employees	Employees 971% decrease	Employees 22344% decrease	Employees 6,5003% increase	Employees 1471% increase	Employees 878% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 340.9 m	Valuation ($) 12.8 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $69.6m (FY, 2025)	Revenue (est.) $3.2b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $25.9m (FY, 2022)
Cost of goods	Cost of goods N/A	Cost of goods $53.9m (FY, 2025)	Cost of goods $984.2m (FY, 2025)	Cost of goods N/A	Cost of goods $28.4m (FY, 2022)
Gross profit	Gross profit N/A	Gross profit $15.8m (FY, 2025)	Gross profit $2.3b (FY, 2025)	Gross profit N/A	Gross profit ($2.5m) (FY, 2022)
Net income	Net income N/A	Net income ($81.3m) (FY, 2025)	Net income ($207.9m) (FY, 2025)	Net income N/A	Net income ($32.1m) (FY, 2022)
Funding
Total funding raised	Total funding raised $ 32m	Total funding raised $ 75m	Total funding raised $ 874.3m	Total funding raised $ 28m	Total funding raised $ 15.9m